{"id":120108,"date":"2026-01-12T05:23:20","date_gmt":"2026-01-12T13:23:20","guid":{"rendered":"https:\/\/ixcellsbiotech.com\/?p=120108"},"modified":"2026-01-12T06:31:18","modified_gmt":"2026-01-12T14:31:18","slug":"ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer","status":"publish","type":"post","link":"https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/","title":{"rendered":"iXCells Biotechnologies Appoints Steve Smith as Chief Executive Officer"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"CEO\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

iXCells Biotechnologies Appoints Steve Smith as Chief Executive Officer<\/b>\n<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

San Diego, CA, 12 January 2026: iXCells Biotechnologies, (\u201ciXCells\u201d) a leading provider of human cell-based solutions and custom iPSC services, today announced the appointment of Steve Smith as CEO. Previously CCO, Steve will lead the Company to advance execution and delivery of iXCells\u2019 bespoke human-derived iPSC preclinical services as demand increases for scalable, high-quality, and human relevant preclinical models.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Steve has over 25 years\u2019 experience in the life sciences industry, with a career spanning senior commercial leadership roles across global life science tools and service organizations. Holding leadership positions at Thermo Fisher and Abcam, including North American Sales Leader and Vice President of Cell Lines, Steve most recently served as CCO at seqWell, a provider of genomic library and multiplexing workflow solutions. Steve\u2019s appointment as CEO marks a significant milestone for iXCells as the Company transitions into its next phase of growth, supporting larger, more complex preclinical programs and expanding multi-study collaborations with biotech, pharmaceutical, academic, and CRO partners.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

Two Major Initiatives are Shaping the Next Phase of Growth<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

During Steve\u2019s time as CCO, iXCells has introduced two major initiatives shaping the Company\u2019s next phase of growth. The launch of iPSCore, iXCells\u2019 discovery support platform designed for precision drug development in rare diseases, delivers comprehensive project management and assay development capabilities to accelerate the translation of complex research into actionable results. Steve also leads Project Mosaic<\/a>, a pilot project developing patient-specific models of sporadic ALS by adapting methods from cancer research.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u201cSteve\u2019s appointment marks a pivotal moment for iXCells,\u201d<\/em> said Alex Gulotta, Principal at Great Point Partners.<\/strong> \u201cHis strategic vision and deep expertise in iPSC technologies and human cell-based research are exactly what we need to accelerate our mission. With initiatives like iPSCore and Project Mosaic already gaining traction under his leadership, I\u2019m confident that Steve will guide iXCells to new heights of scientific innovation and impact.\u201d<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

Empowering Scientists With Human-relevant Disease Models <\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Steve Smith, CEO, iXCells Biotechnologies said:<\/strong> \u201ciXCells\u2019 mission is to empower scientists with high-quality, human-relevant disease models and tools to support personalized solutions that enable breakthrough discoveries.<\/em> I am excited to lead iXCells through this next stage of growth, expanding our iPSCore end to end services, delivering actionable results in ongoing scientific partnerships,<\/em> and providing customers with the consistency, scale, and collaboration required to advance complex discovery programs to enable the development of novel therapeutics for rare and complex diseases\u201d<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

The Company Remains Dedicated to Advancing Scientific Discovery<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

This appointment strengthens the leadership team as iXCells focuses on expanding its portfolio of custom-tailored iPSC products and delivery of enhanced preclinical services to advance scientific discovery.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

About iXCells Biotechnologies<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

iXCells Biotechnologies (\u201ciXCells\u201d) is a leading San Diego, California-based cell technology company focused on generating a wide variety of predictive human disease models. In addition, iXCells is pursuing custom and patient-specific services leveraging its expertise in the preparation, handling, engineering and differentiation of induced pluripotent stem cells (iPSCs) and in the isolation of primary cells along with associated services for descriptive and functional cell characterization, compound screening and toxicology testing.<\/p>

The company\u2019s mission is to supply a diverse range of human disease models, derived from ethically sourced patient and healthy donor tissues, to support academic, pharmaceutical, and clinical researchers globally. By providing predictive human cell models, we aim to deepen the understanding of the molecular mechanisms underlying disease onset and progression as much as slow-down or reversion of disease, and accelerate the discovery and development of new medicines and innovative therapies to further advance precision medicine.<\/p>

Media Contacts<\/strong><\/p>

Christy Holt
Director of Marketing
christy.holt@ixcellsbiotech.com
iXCellsBiotech.com<\/a><\/p>

To request more information visit
iXCells on Linkedin,<\/a>
and iXCells on YouTube.<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
COMPANY NEWS<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t<\/i>\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t
\n\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tiXCells Biotechnologies appoints Steve Smith as CEO\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\tThis leadership transition supports the company\u2019s next phase of strategic growth, aimed at expanding its portfolio of custom-tailored iPSC products and delivery of enhanced preclinical services.\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tCONTACT US TODAY<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

iXCells Biotechnologies develops a diverse range of off-the-shelf and custom iPSC-derived cell models\u2014sourced from both healthy and patient donors\u2014with the goal of enabling \u201cclinical-trials-in-a-plate.\u201d<\/p>\n","protected":false},"author":234903467,"featured_media":120448,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"elementor_header_footer","format":"standard","meta":{"_acf_changed":false,"content-type":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_wpcom_ai_launchpad_first_post":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"{title}\n\n{excerpt}\n\n{url}","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"_wpas_customize_per_network":false,"jetpack_post_was_ever_published":true},"categories":[1889],"tags":[],"news_type":[2168],"news_areas":[],"class_list":["post-120108","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news","news_type-company-news"],"acf":[],"yoast_head":"\niXCells Biotechnologies Appoints Steve Smith as Chief Executive Officer - iXCells<\/title>\n<meta name=\"description\" content=\"Appointment strengthens leadership team as iXCells focuses on expanding its portfolio of custom-tailored iPSC products and delivery of enhanced preclinical services\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iXCells Biotechnologies Appoints Steve Smith as Chief Executive Officer - iXCells\" \/>\n<meta property=\"og:description\" content=\"Appointment strengthens leadership team as iXCells focuses on expanding its portfolio of custom-tailored iPSC products and delivery of enhanced preclinical services\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"iXCells\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T13:23:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T14:31:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2026\/01\/CEO-Appointment-V03-1800px-780px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1800\" \/>\n\t<meta property=\"og:image:height\" content=\"780\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tom Faulkner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@iXCells\" \/>\n<meta name=\"twitter:site\" content=\"@iXCells\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tom Faulkner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\\\/\"},\"author\":{\"name\":\"Tom Faulkner\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#\\\/schema\\\/person\\\/5de2572b7775a5dad73cdc1da275cfe4\"},\"headline\":\"iXCells Biotechnologies Appoints Steve Smith as Chief Executive Officer\",\"datePublished\":\"2026-01-12T13:23:20+00:00\",\"dateModified\":\"2026-01-12T14:31:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\\\/\"},\"wordCount\":664,\"publisher\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ixcellsbiotech.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/CEO-Appointment-V03-1800px-780px.jpg\",\"articleSection\":[\"Company News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\\\/\",\"url\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\\\/\",\"name\":\"iXCells Biotechnologies Appoints Steve Smith as Chief Executive Officer - iXCells\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ixcellsbiotech.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/CEO-Appointment-V03-1800px-780px.jpg\",\"datePublished\":\"2026-01-12T13:23:20+00:00\",\"dateModified\":\"2026-01-12T14:31:18+00:00\",\"description\":\"Appointment strengthens leadership team as iXCells focuses on expanding its portfolio of custom-tailored iPSC products and delivery of enhanced preclinical services\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ixcellsbiotech.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/CEO-Appointment-V03-1800px-780px.jpg\",\"contentUrl\":\"https:\\\/\\\/ixcellsbiotech.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/CEO-Appointment-V03-1800px-780px.jpg\",\"width\":1800,\"height\":780},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ixcellsbiotech.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iXCells Biotechnologies Appoints Steve Smith as Chief Executive Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#website\",\"url\":\"https:\\\/\\\/ixcellsbiotech.com\\\/\",\"name\":\"iXCells Biotechnologies\",\"description\":\"Human Relevant Cell Model Expert | iPSC | Primary Cells\",\"publisher\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ixcellsbiotech.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#organization\",\"name\":\"iXCells Biotechnologies USA, Inc.\",\"url\":\"https:\\\/\\\/ixcellsbiotech.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ixcellsbiotech.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Logo.png\",\"contentUrl\":\"https:\\\/\\\/ixcellsbiotech.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Logo.png\",\"width\":256,\"height\":64,\"caption\":\"iXCells Biotechnologies USA, Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/iXCells\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ixcells-biotechnologies\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#\\\/schema\\\/person\\\/5de2572b7775a5dad73cdc1da275cfe4\",\"name\":\"Tom Faulkner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7c1757209491e07c143af4c5449426c0a2e5362a8d2c2d7e874c17cd9a17264b?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7c1757209491e07c143af4c5449426c0a2e5362a8d2c2d7e874c17cd9a17264b?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7c1757209491e07c143af4c5449426c0a2e5362a8d2c2d7e874c17cd9a17264b?s=96&d=identicon&r=g\",\"caption\":\"Tom Faulkner\"},\"url\":\"https:\\\/\\\/ixcellsbiotech.com\\\/author\\\/tfaulkner\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"iXCells Biotechnologies Appoints Steve Smith as Chief Executive Officer - iXCells","description":"Appointment strengthens leadership team as iXCells focuses on expanding its portfolio of custom-tailored iPSC products and delivery of enhanced preclinical services","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/","og_locale":"en_US","og_type":"article","og_title":"iXCells Biotechnologies Appoints Steve Smith as Chief Executive Officer - iXCells","og_description":"Appointment strengthens leadership team as iXCells focuses on expanding its portfolio of custom-tailored iPSC products and delivery of enhanced preclinical services","og_url":"https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/","og_site_name":"iXCells","article_published_time":"2026-01-12T13:23:20+00:00","article_modified_time":"2026-01-12T14:31:18+00:00","og_image":[{"width":1800,"height":780,"url":"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2026\/01\/CEO-Appointment-V03-1800px-780px.jpg","type":"image\/jpeg"}],"author":"Tom Faulkner","twitter_card":"summary_large_image","twitter_creator":"@iXCells","twitter_site":"@iXCells","twitter_misc":{"Written by":"Tom Faulkner","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/#article","isPartOf":{"@id":"https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/"},"author":{"name":"Tom Faulkner","@id":"https:\/\/ixcellsbiotech.com\/#\/schema\/person\/5de2572b7775a5dad73cdc1da275cfe4"},"headline":"iXCells Biotechnologies Appoints Steve Smith as Chief Executive Officer","datePublished":"2026-01-12T13:23:20+00:00","dateModified":"2026-01-12T14:31:18+00:00","mainEntityOfPage":{"@id":"https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/"},"wordCount":664,"publisher":{"@id":"https:\/\/ixcellsbiotech.com\/#organization"},"image":{"@id":"https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2026\/01\/CEO-Appointment-V03-1800px-780px.jpg","articleSection":["Company News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/","url":"https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/","name":"iXCells Biotechnologies Appoints Steve Smith as Chief Executive Officer - iXCells","isPartOf":{"@id":"https:\/\/ixcellsbiotech.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/#primaryimage"},"image":{"@id":"https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2026\/01\/CEO-Appointment-V03-1800px-780px.jpg","datePublished":"2026-01-12T13:23:20+00:00","dateModified":"2026-01-12T14:31:18+00:00","description":"Appointment strengthens leadership team as iXCells focuses on expanding its portfolio of custom-tailored iPSC products and delivery of enhanced preclinical services","breadcrumb":{"@id":"https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/#primaryimage","url":"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2026\/01\/CEO-Appointment-V03-1800px-780px.jpg","contentUrl":"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2026\/01\/CEO-Appointment-V03-1800px-780px.jpg","width":1800,"height":780},{"@type":"BreadcrumbList","@id":"https:\/\/ixcellsbiotech.com\/ixcells-biotechnologies-appoints-steve-smith-as-chief-executive-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ixcellsbiotech.com\/"},{"@type":"ListItem","position":2,"name":"iXCells Biotechnologies Appoints Steve Smith as Chief Executive Officer"}]},{"@type":"WebSite","@id":"https:\/\/ixcellsbiotech.com\/#website","url":"https:\/\/ixcellsbiotech.com\/","name":"iXCells Biotechnologies","description":"Human Relevant Cell Model Expert | iPSC | Primary Cells","publisher":{"@id":"https:\/\/ixcellsbiotech.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ixcellsbiotech.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ixcellsbiotech.com\/#organization","name":"iXCells Biotechnologies USA, Inc.","url":"https:\/\/ixcellsbiotech.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ixcellsbiotech.com\/#\/schema\/logo\/image\/","url":"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2023\/06\/Logo.png","contentUrl":"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2023\/06\/Logo.png","width":256,"height":64,"caption":"iXCells Biotechnologies USA, Inc."},"image":{"@id":"https:\/\/ixcellsbiotech.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/iXCells","https:\/\/www.linkedin.com\/company\/ixcells-biotechnologies"]},{"@type":"Person","@id":"https:\/\/ixcellsbiotech.com\/#\/schema\/person\/5de2572b7775a5dad73cdc1da275cfe4","name":"Tom Faulkner","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7c1757209491e07c143af4c5449426c0a2e5362a8d2c2d7e874c17cd9a17264b?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7c1757209491e07c143af4c5449426c0a2e5362a8d2c2d7e874c17cd9a17264b?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7c1757209491e07c143af4c5449426c0a2e5362a8d2c2d7e874c17cd9a17264b?s=96&d=identicon&r=g","caption":"Tom Faulkner"},"url":"https:\/\/ixcellsbiotech.com\/author\/tfaulkner\/"}]}},"jetpack_publicize_connections":[],"jetpack_shortlink":"https:\/\/wp.me\/peN4gs-vfe","jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2026\/01\/CEO-Appointment-V03-1800px-780px.jpg","_links":{"self":[{"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/posts\/120108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/users\/234903467"}],"replies":[{"embeddable":true,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/comments?post=120108"}],"version-history":[{"count":15,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/posts\/120108\/revisions"}],"predecessor-version":[{"id":120474,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/posts\/120108\/revisions\/120474"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/media\/120448"}],"wp:attachment":[{"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/media?parent=120108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/categories?post=120108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/tags?post=120108"},{"taxonomy":"news_type","embeddable":true,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/news_type?post=120108"},{"taxonomy":"news_areas","embeddable":true,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/news_areas?post=120108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}